Bringing the Power of AI to Early Cancer Detection

Detecting 6+ cancer types

OneTest is now available Globally

Now clinics and other medical providers can easily start offering A.I. based cancer screening with OneTest today using a cloud accessible portal.

Integration into existing biomarker based cancer screening programs

Adoption as a new stand-alone cancer screening offering

What is OneTest?

OneTestTM is among the first multi-cancer screening panels to harness the power of Ai to improve the accuracy and usefulness of affordable tumor marker tests to help identify 6 or more types of cancer.

Based on commonly ordered tumor markers such as PSA, CEA, AFP, CA-125 and others, OneTest can aid in the early detection of many types of cancer, including those not typically screen for such as lung, liver, pancreas, etc. OneTestTM is powered by real-world cancer-screening results of tens of thousands of people and is poised for continuous learning and advancement as the algorithms are exposed to more real-world data.

Multi-cancer screening that assesses risk for more than 6 common cancers.

Allows patients to track and manage their cancer marker value regardless of which doctor they use.

OneTest Improves Cancer Screening

AI

OneTest uses cutting edge artificial intelligence and big data to dramatically enhance test sensitivity and early detection

Cancer Risk Management

One of a kind Biomarker velocity tracking graph which allows health care professionals and patients to visualize deviations in biomarker levels to assist in cancer detection through serial testing.

Oncomarkers

OneTest’s biomarker panel consists of well established and readily available markers used by tens of millions of people per-year for screening in Asia

Affordability

OneTest is highly affordable, because it relies on a locally executed blood analysis, which allows for patient price flexibility to be determined by the local market

No Radiation

OneTest relies on blood based biomarkers for screening rather than invasive or harmful radiation imaging

Male
Biomarker
only
40.3%
With AI 82.3%
 
2x Increase in sensitivity
Female
  11.5%
With AI 74.8%
 
6x Increase in sensitivity

Improved Sensitivity

OneTestTM can significantly increase cancer detection rates by identifying important patterns in tumor marker results, which might fall below the standard manufacturers cutoff values.

How does OneTest Work?

1

Analyze blood specimen for tumor markers on Roche, Abbott, or other approved instrument

2

Complete patient health history via a 3-minute online questionnaire

3

Generate Onetest report by entering relevant health history and biomarker results into OneTest cloud algorithm

4

Follow up with appropriate diagnostic imaging or repeat OneTest, if needed

1

Analyze blood specimen for tumor markers on Roche, Abbott, or other approved instrument

2

Complete patient health history via a 3-minute online questionnaire.

3

Generate Onetest report by enter health history and biomarker results into OneTest cloud algorithm

4

Follow up with appropriate diagnostic imaging or repeat OneTest, if needed.

Who is OneTest For?

Access to the OneTest portal is available anywhere in the world through various models of subscription agreements

Hospitals

Hospitals, large or small can offer OneTest as part of their outpatient services

Clinics

A wide range of clinics can help draw in new patients by introducing them to OneTest's cutting edge technology

Health Check Centers

Health check centers offering advanced physicals are ideal candidates to include OneTest into their spectrum of options

Labs

Labs can easily integrate OneTest into their offering for both B2B and B2C

Medical Business

Other medical business have had success introducing OneTest into new markets

OneTest has been adopted for use in these countries

Contact us if you are interested in offering OneTest today

USA
Japan
Korea
UAE
Argentina
Taiwan
China
Jordan
Austria

Compatibility

OneTest has been validated to run using the results of these laboratory instrument platforms.

Required Biomarkers

Male Panel (6 markers)
AFP, CEA, CA 19-9, CYFRA 21-1, SCC, PSA

Female Panel (7 markers)
AFP, CEA, CA 19-9, CYFRA 21-1, SCC, CA 125, CA 15-3

Compatible Instruments

Abbott Architect i2000
Roche Elecsys Cobas
Siemens Advia Centaur
Beckman UniCel Dxl 800

OneTest by 2020 GeneSystems

20/20 is a USA-based cancer diagnostics company, which develops cancer diagnostic products since 2008. It has created proprietary tests for lung and other types of cancer and operates a CLIA certified laboratory, catering to the needs of American based patients and clinics.

Contact us to learn more

Close Menu

World Wide Clinics offering OneTest

USA

Clinic Details Here

Japan

Clinic Details Here

Korea

Clinic Details Here

UAE

Clinic Details Here

Argentina

Clinic Details Here

Taiwan

Clinic Details Here

China

Clinic Details Here

Jordan

Clinic Details Here

Austria

Clinic Details Here

Get 30 days trial

Send us your details, we will contact you to give you a 30 days trial